WASHINGTON, D.C. 20549

---

FORM 8-K

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 25, 2024

(Exact Name of Registrant as Specified in its Charter)

 

 

Registrant’s telephone number, including area code: (781) 663-6900

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 25, 2024, Dr. Sylvie Grégoire, a member of the Board of Directors (the “Board”) of Revvity, Inc. (“Revvity” or the “Company”) notified the Company of her decision not to stand for re-election to the Board at the annual meeting of shareholders of the Company scheduled to occur on April 23, 2024.  Dr. Grégoire’s decision not to stand for re-election is not due to any disagreement between Dr. Grégoire and the Company relating to the Company’s operations, policies or practices.

On January 25, 2024, the Board elected Michael A. Klobuchar and Sophie V. Vandebroek to serve on the Board, effective February 1, 2024.  Neither Mr. Klobuchar nor Ms. Vandebroek will serve on a committee of the Board upon their election to the Board.

In connection with their election to the Board,  each of Mr. Klobuchar and Ms. Vandebroek will receive a stock award of Revvity common stock with a fair market value of $22,500 and a grant of restricted stock units with a fair market value of $27,500, representing the annual equity compensation payable to the Company’s non-employee directors under the Company’s non-employee director compensation program, prorated to reflect the remaining portion of the Board service year.  Each award will be made on the customary terms and conditions of grants to Revvity’s non-employee directors.  In addition, each of Mr. Klobuchar and Ms. Vandebroek will be eligible to be paid the Company’s annual cash retainer for non-employee directors of $90,000, also prorated to reflect the remaining portion of the Board service year.

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.